Biomarkers identified in acute myelogenous leukemia


In the March 22 issue, the New England Journal of Medicine will publish findings indicating that researchers from Memorial Sloan-Kettering's Human Oncology Pathogenesis Program are on the cusp of a prognostic breakthrough with regard to patients with acute myelogenous leukemia (AML).

According to the paper, researchers have identified a set of genetic abnormalities in patients with AML that can aide oncologists in making more accurate predictions about the prognosis of these patients.

The genetic abnormalities, better termed as genetic biomarkers should also enable doctors to determine which therapies will most likely benefit which AML patients--whether that means high-dose chemotherapy, palliative care, or a stem cell transplantation.

Source: Medical News Today

LymphomaInfo Social